| Literature DB >> 31615067 |
Shazia Rehman1, Xi Li2, Chao Wang3, Muhammad Ikram4, Erum Rehman5, Meina Liu6.
Abstract
A wide variation exists in the practice patterns of acute myocardial infarction (AMI) care worldwide, leading to differences in clinical outcomes. This study aims to evaluate the quality of process care and its impact on in-hospital outcomes among AMI patients in Pakistan, as no such study has been conducted in Pakistan thus far based upon recommended guidelines. We investigated a sample of 2663 AMI patients across 11 territory hospitals in Punjab province of Lahore, Faisalabad, Multan, Rawalpindi, and Islamabad from January 1, 2016 to December 31, 2017, with an in-hospital mortality rate of 8.6%. We calculated compliance rates of quality indicators (QIs) for all eligible patients. The association between process care and in-hospital outcome was assessed using hierarchical generalized linear model that adjusted for patient and hospital characteristics. In addition, we examined the effect of patient composite scores on clinical outcomes. Aspirin (73.08%) and clopidogrel (67.86%) indicated relatively better conformance than other QIs. The percutaneous coronary intervention also showed significantly low adherence. All QIs showed no significant association with in-hospital mortality. In contrast, 4 out of 8 QIs were observed positively correlated with in-hospital length of stay (LOS). The overall patient composite score was found to be statistically significant with in-hospital LOS. The assessment of quality of care showed low adherence to clinical care recommendations, and increased adherence was associated with longer in-hospital LOS among AMI patients. Evaluation of valid QIs for AMI treatment and their impact on in-hospital outcomes is an important tool for improving health care delivery in the overall AMI population in Pakistan. Low adherence to performance measures strongly compel to focus on guideline-based tools for AMI in Pakistan.Entities:
Keywords: acute myocardial infarction; compliance measurement; composite score; in-hospital outcomes; quality of care
Mesh:
Year: 2019 PMID: 31615067 PMCID: PMC6844119 DOI: 10.3390/ijerph16203890
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Univariate relationship between patient characteristics and outcome measures.
| Patient Characteristics | Frequency (%) | In-Hospital Mortality | LOS (day) | ||
|---|---|---|---|---|---|
| N (%) | mean ± SD | ||||
| Age | |||||
| ~50 | 316 (11.87) | 26 (8.23) | 0.8170 | 6.07 ± 3.05 | <0.0001 |
| 50–60 | 414 (15.55) | 32 (7.73) | 7.27 ± 2.50 | ||
| 60–70 | 736 (27.64) | 61 (8.29) | 7.64 ± 2.29 | ||
| 70~ | 1197 (44.95) | 109 (9.11) | 7.41 ± 2.50 | ||
| Sex | |||||
| Male | 1859 (69.81) | 159 (8.55) | 0.9803 | 7.33 ± 2.55 | 0.6370 |
| Female | 804 (30.19) | 69 (8.58) | 7.29 ± 2.59 | ||
| Obese | |||||
| No | 2314 (86.89) | 201 (8.69) | 0.5544 | 7.37 ± 2.53 | 0.0045 |
| Yes | 349 (13.11) | 27 (7.74) | 6.96 ± 2.69 | ||
| Insurance | |||||
| Government | 673 (25.27) | 60 (8.92) | 0.9177 | 7.16 ± 2.77 | 0.0040 |
| Private | 341 (12.81) | 28 (8.21) | 7.49 ± 2.78 | ||
| Uninsured | 1649 (61.92) | 140 (8.49) | 7.70 ± 2.46 | ||
| Smoking | |||||
| No | 1162 (43.63) | 95 (8.18) | 0.5308 | 7.32 ± 2.57 | 0.2555 |
| Yes | 1501 (56.37) | 133 (8.86) | 7.31 ± 2.55 | ||
| Family history of IHD * | |||||
| No | 1536 (57.68) | 132 (8.59) | 0.9451 | 7.24 ± 2.58 | 0.1109 |
| Yes | 1127 (42.32) | 96 (8.52) | 7.42 ± 2.53 | ||
| Prior MI/CAD | |||||
| No | 1693 (63.57) | 153 (9.04) | 0.2467 | 7.23 ± 2.58 | 0.0214 |
| Yes | 970 (36.43) | 75 (7.73) | 7.46 ± 2.58 | ||
| History Of DM | |||||
| No | 1754 (65.87) | 151 (8.61) | 0.9039 | 7.26 ± 2.62 | 0.2349 |
| Yes | 909 (34.13) | 77 (8.47) | 7.41 ± 2.42 | ||
| History of Hypertension | |||||
| No | 1611 (60.50) | 130 (8.07) | 0.2612 | 7.20 ± 2.40 | 0.0151 |
| Yes | 1052 (39.50) | 98 (9.32) | 7.48 ± 2.48 | ||
| MI | |||||
| NSTEMI | 1209 (45.40) | 124 (10.26) | 0.0044 | 6.09 ± 2.65 | <0.0001 |
| STEMI | 1454 (54.60) | 104 (7.15) | 8.33 ± 1.96 | ||
| Hospital type | |||||
| Specialized | 1034 (38.83) | 103 (9.96) | 0.0397 | 7.08 ± 2.64 | <0.0001 |
| Generalized | 1629 (61.17) | 125 (7.67) | 7.46 ± 2.49 | ||
* There is 1 missing value. Abbreviation: LOS, length of stay; SD, standard deviation; MI, Myocardial Infarction; IHD, Ischemic Heart Disease; DM, Diabetes Mellitus; CAD, Coronary Artery Disease; STEMI, ST-elevation myocardial infarction; NSTEMI, Non-ST-elevation myocardial infarction.
Univariate analysis of comorbidities with in-hospital mortality and length of stay.
| Comorbidities | Frequency (%) | In-Hospital Mortality | LOS (day) | ||
|---|---|---|---|---|---|
| N (%) | Mean ± SD | ||||
| Rheumatic | |||||
| no | 2655 (99.70) | 226 (8.51) | 0.0002 | 7.32 ± 2.56 | 0.8367 |
| yes | 8 (0.30) | 2 (25.00) | 6.88 ± 3.18 | ||
| Heart Failure | |||||
| no | 2615 (98.20) | 222 (8.49) | 0.3251 | 7.31 ± 2.56 | 0.9827 |
| yes | 48 (1.80) | 6 (12.50) | 7.35 ± 2.37 | ||
| Cardiogenic Shock | |||||
| no | 2392 (89.82) | 204 (8.53) | 0.8550 | 7.27 ± 2.57 | 0.0137 |
| yes | 271 (10.18) | 24 (8.86) | 7.68 ± 2.43 | ||
| Hypertension | |||||
| no | 1998 (75.03) | 167 (8.36) | 0.5155 | 7.30 ± 2.57 | 0.8212 |
| yes | 665 (24.97) | 61 (9.17) | 7.35 ± 2.53 | ||
| Cerebrovascular disease | |||||
| no | 2253 (84.60) | 205 (9.10) | 0.0022 | 7.29 ± 2.60 | 0.5060 |
| yes | 410 (15.40) | 23 (5.61) | 7.43 ± 2.32 | ||
| Gastrointestinal disease | |||||
| no | 2620 (98.39) | 226 (8.63) | 0.3555 | 7.32 ± 2.56 | 0.5060 |
| yes | 43 (1.61) | 2 (4.65) | 7.05 ± 2.54 | ||
| Type-I DM | |||||
| no | 2307 (86.63) | 200 (8.67) | 0.6138 | 7.29 ± 2.60 | 0.5357 |
| yes | 356 (13.37) | 28 (7.87) | 7.48 ± 2.26 | ||
| Type-II DM | |||||
| no | 2322 (87.19) | 197 (8.48) | 0.7084 | 7.33 ± 2.56 | 0.4519 |
| yes | 341 (12.81) | 31 (9.09) | 7.23 ± 2.52 | ||
| Renal failure | |||||
| no | 2451 (92.04) | 206 (8.40) | 0.3247 | 7.34 ± 2.54 | 0.3972 |
| yes | 212 (7.96) | 22 (10.38) | 7.00 ± 2.71 | ||
| Dysrhythmia | |||||
| no | 2485 (93.32) | 216 (8.69) | 0.3689 | 7.29 ± 2.57 | 0.1766 |
| yes | 178 (6.68) | 12 (6.74) | 7.66 ± 2.69 | ||
| Peripheral Vascular Disease | |||||
| no | 2389 (89.71) | 201 (8.41) | 0.4196 | 7.30 ± 2.58 | 0.9493 |
| yes | 274 (10.29) | 27 (9.85) | 7.41 ± 2.32 | ||
| COPD | |||||
| no | 2525 (94.82) | 215 (8.51) | 0.7113 | 7.30 ± 2.56 | 0.1561 |
| yes | 138 (5.18) | 13 (9.42) | 7.61 ± 2.43 | ||
| Liver disease | |||||
| no | 2615 (98.20) | 224 (8.57) | 0.9545 | 7.31 ± 2.56 | 0.4408 |
| yes | 48 (1.80) | 4 (8.33) | 7.60 ± 2.44 | ||
| Hypercholesterolemia | |||||
| no | 1614 (60.61) | 140 (8.67) | 0.7972 | 7.22 ± 2.59 | 0.0499 |
| yes | 1049 | 88 (8.39) | 7.46 ± 2.50 | ||
| Thyroid Disorder | |||||
| no | 1950 | 175 (8.97) | 0.2082 | 7.19 ± 2.62 | <0.0001 |
| yes | 713 | 53 (7.43) | 7.65 ± 2.34 | ||
Abbreviation: LOS, length of stay; SD, standard deviation; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus.
Figure 1Regression coefficients estimation for in-house mortality and length of stay.
Adherence to performance measures.
| Quality Indicators (QI) | Eligible Patients, No. (%) a | Overall Adherence, % | Hospital Variation, Range (%) |
|---|---|---|---|
| QI1: Aspirin prescribed within 3h of hospital arrival | 1549 (58.17) | 73.08 | 62.11–85.81 |
| QI2: Beta-blockers within 12h of arrival | 785 (23.69) | 38.98 | 32.89–45.45 |
| QI3: Clopidogrel within 12h of arrival | 2408 (90.42) | 67.86 | 62.68–73.27 |
| QI4: Thrombolytics received within 30 min of hospital arrival | 971 (36.46) | 7.52 | 3.57–11.43 |
| QI5: ECG within 10 min of hospital arrival | 2663 (100.00) | 62.49 | 57.74–71.84 |
| QI6: Left ventricular function assessment | 2663 (100.00) | 62.79 | 56.33–67.53 |
| QI7: Coronary angiography performed during hospital stay | 2663 (100.00) | 66.35 | 60.85–71.78 |
| QI8: Primary PCI | 2366 (88.85) | 37.36 | 29.52–43.59 |
| Prescription filled post-discharge | |||
| QI9: Aspirin | 1549 (58.17) | 47.97 | 38.51–61.29 |
| QI10: Beta-blocker | 785 (29.48) | 22.29 | 10.94–34.21 |
| QI11: Clopidogrel | 2408 (90.42) | 45.35 | 35.36–53.59 |
| QI12: Statin | 2020 (75.85) | 36.39 | 30.11–41.76 |
| QI13: ACE inhibitor | 2567 (96.40) | 38.02 | 29.70–45.54 |
| Outcome indicators | |||
| In-hospital mortality | 2663 (100.00) | 8.56 | 5.56–12.50 |
Abbreviation: PCI, percutaneous coronary intervention. a Eligible patients are those with definite indications but no documented contraindications.
Association of process measures with clinical outcomes among acute myocardial infarction patients.
| Quality Indicators* | In−Hospital Mortality | Length of Stay | ||
|---|---|---|---|---|
| Adjusted β | Unadjusted β | Adjusted β | Unadjusted β | |
| QI1 | −0.0258 (0.9014) | −0.0382 (0.8540) | 0.1668 (0.1880) | 0.2930 (0.0340) |
| QI2 | 0.1174 (0.6616) | 0.1079 (0.6856) | 0.1873 (0.2207) | 0.2337 (0.1456) |
| QI3 | 0.0238 (0.8831) | 0.0156 (0.9229) | 0.5278 (<0.0001) | 0.7994 (<0.0001) |
| QI4 | 0.5451 (0.1898) | 0.6093 (0.1457) | −0.4913 (0.0351) | −0.4994 (0.0328) |
| QI5 | 0.0342 (0.8177) | 0.0525 (0.7229) | −0.2179 (0.0159) | −0.2913 (0.0043) |
| QI6 | 0.0048 (0.9742) | −0.0636 (0.6647) | 0.4251 (<0.0001) | 0.8413 (<0.0001) |
| QI7 | −0.0786 (0.6057) | −0.1535 (0.3110) | 0.9974 (<0.0001) | 1.5171 (<0.0001) |
| QI8 | −0.1276 (0.4603) | −0.2174 (0.2102) | 1.2699 (<0.0001) | 1.7515 (<0.0001) |
* The definition of quality indicators (QIs) please refer to Table 3. All significant (p < 0.10) risks factors (listed in Table 1) in univariate analysis for patient characters were included in the hierarchical generalized linear model.
Effect of patient composite scores on in−hospital mortality.
| Factors | Regression Coefficient, 95%CI | |
|---|---|---|
| STEMI vs. NSTEMI | 1.451 (1.026, 2.053) | 0.0379 |
| Generalized vs. Specialized Hospital | 0.877 (0.613, 1.254) | 0.4270 |
| Cerebra disease | 0.620 (0.355, 1.082) | 0.0849 |
| Rheumatic Heart Disease (RHD) | 2.346 (0.070, 78.121) | 0.4952 |
| Composite score (per 10%) | 1.003 (0.937, 1.073) | 0.9284 |
The composite score was added as a continuous predictor variable, and regression coefficients were reported per 10% increment in composite score. Abbreviation: STEMI, ST-elevation myocardial infarction; NSTEMI, Non-ST-elevation myocardial infarction.
Effect of patient composite scores on length of stay.
| Factors | Regression Coefficient, 95%CI | |
|---|---|---|
| Age | ||
| 50–60 vs. ~50 | 0.481 (0.132, 0.829) | 0.0069 |
| 60–70 vs. ~50 | 0.751 (0.432, 1.071) | <0.0001 |
| 70~ vs. ~50 | 0.587 (0.282, 0.891) | 0.0002 |
| Insurance | ||
| Government vs. Uninsured | 0.147 (−0.059, 0.354) | 0.1623 |
| Private vs. Uninsured | 0.202 (−0.069, 0.474) | 0.1443 |
| Prior MI/CAD | 0.021 (−0.210, 0.251) | 0.8595 |
| History of Hypertension | 0.137 (−0.091, 0.365) | 0.2401 |
| STEMI vs. NSTEMI | 2.049 (1.871, 2.227) | <0.0001 |
| Generalized vs. Specialized hospital | 0.168 (−0.164, 0.499) | 0.3213 |
| thyroid | 0.257 (0.058, 0.455) | 0.011 |
| lipids | 0.179 (−0.001, 0.359) | 0.051 |
| Composite score (per 10%) | 0.258 (0.217, 0.299) | <0.0001 |
The composite score was added as a continuous predictor variable, and regression coefficients were reported per 10% increment in composite score. Abbreviation: MI, Myocardial Infarction; CAD, Coronary Artery Disease; STEMI, ST-elevation myocardial infarction; NSTEMI, Non-ST-elevation myocardial infarction.